http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S63112512-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5929f2d6f4dba84be8dd3a8ba633db12
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20
filingDate 1986-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_664dfe59aef54646fe1b8e686fec2389
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c989eaadc33a42856108c4a9f9dd372b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_242e04168bb4551baa483c21b1e9432d
publicationDate 1988-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-S63112512-A
titleOfInvention Liposome preparation and production thereof
abstract PURPOSE: To obtain a liposome preparation circulating in the body stably over a long period accompanied by blood when administered by intravenous injection, by sealing a drug in a liposome having a membrane-constituting component consisting of a phospholipid having a saturated acyl group as the acyl group and a glycolipid having sulfuric acid group. n CONSTITUTION: A liposome membrane having a phase-transition temperature of about 37W60°C, preferably about 40W55°C is produced by using (A) a phospholipid having saturated acyl group as the acyl group, e.g., dipalmitoylphosphatidylcholine and (B) a glycolipid having sulfuric acid group, preferably a sulfatide in an amount of about 0.5W50pts.wt., preferably about 2W20pts.wt. of the component B based on 100pts.wt. of the component A in the sealing of a drug in a liposome. A liposome preparation produced by the process is effective in mitigating the intrinsic toxicity of a drug by the above- mentioned effect, capable of improving the target effect of the drug to a specific focus and improving the long-acting remedy effect of the drug and especially suitable for the thermotherapy of cancer. n COPYRIGHT: (C)1988,JPO&Japio
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H0616536-A
priorityDate 1986-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID447693
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413933
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1118
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226416522
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5459389
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419521634
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226416521
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID452110
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87059454
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419572081
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412584819

Total number of triples: 28.